Drug Information

Drug General Information
Drug ID
D0B1TI
Former ID
DNCL003541
Drug Name
MPSK3169A
Synonyms
RG7652
Indication Cardiovascular disorder [ICD10:I00-I99] Phase 2 [523923]
Metabolic disorders [ICD9: 270-279; ICD10:E70-E89] Phase 1 [549836]
Company
Genentech
Target and Pathway
Target(s) mRNA of proprotein convertase subtilisin/kexin type 9 Target Info Modulator [543615]
WikiPathways PCSK9-mediated LDLR degradation
References
Ref 523923ClinicalTrials.gov (NCT01609140) A Phase II Study of the Safety and Efficacy of MPSK3169A in Patients With Coronary Heart Disease or High Risk of Coronary Heart Disease. U.S. National Institutes of Health.
Ref 549836GW24-e2907??ffects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single- and multiple-dose study. Heart 2013;99:A153.
Ref 543615(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2388).

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.